Interim analysis of phase 3 RCT (211 Chinese patients, EGFR-mutant MET-amplified NSCLC after EGFR TKI): savolitinib-osimertinib prolonged median PFS vs chemotherapy in TKI-naive (9.8 vs 5.4 months; HR 0.34) and ITT groups; grade ≥3 AEs 57% each.
RCTn = 211
Lu et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial